Abilify · DIN 02322412 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Savings card: innoviCares lists Abilify (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Abilify · DIN 02322412
Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2011-10-25
Health Canada: Marketed since 2018-11-02 · brand ABILIFY · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 20 MG · company Otsuka pharmaceutical co ltd · schedule Prescription
Ministry pays: $1.0017 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02322412)
Source record
DIN 02322412: Abilify
Raw flags: sec3=Y
Item: 281608305; group id 478; item number 1214; lccId None; manufacturer id OTS
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $4.1028; ministry $1.0017
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02322412
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80786
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Apo-Aripiprazole · DIN 02471124 · $1.0017
Aripiprazole · DIN 02506750 · $1.0017
Aripiprazole · DIN 02534363 · $1.0017
Auro-Aripiprazole · DIN 02460076 · $1.0017
Jamp Aripiprazole · DIN 02553228 · $1.0017
Mint-Aripiprazole · DIN 02483599 · $1.0017
NRA-Aripiprazole · DIN 02472260 · $1.0017
PMS-Aripiprazole · DIN 02466686 · $1.0017
Sandoz Aripiprazole · DIN 02473690 · $1.0017
Teva-Aripiprazole · DIN 02464187 · $1.0017
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02322412
Shortage record checked October 6, 2026